MCID: SRC014
MIFTS: 64

Sarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Sarcoma

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma 12 29 54 6 15 17 70
Connective and Soft Tissue Neoplasm 12
Tumor of Soft Tissue and Skeleton 12
Sarcoma - Category 70
Sarcomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:1115
ICD9CM 34 171.9
SNOMED-CT 67 93765001
ICD10 32 C49
UMLS 70 C0153519 C1261473 C1299262

Summaries for Sarcoma

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to spindle cell sarcoma and ewing sarcoma. An important gene associated with Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Aprepitant and Lopinavir have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 A sarcoma is a malignant tumor, a type of cancer that arises from transformed cells of mesenchymal... more...

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2189)
# Related Disease Score Top Affiliating Genes
1 spindle cell sarcoma 33.9 SSX2 SSX1 KIT EWSR1
2 ewing sarcoma 33.8 TP53 SSX1 KRAS KIT FLI1 EWSR1
3 sarcoma, synovial 33.7 SSX2 SSX1 KIT FLI1 EWSR1
4 li-fraumeni syndrome 33.2 TP53 RB1 KRAS HRAS CHEK2
5 ewing sarcoma of bone 33.1 FLI1 FES EWSR1
6 heart sarcoma 33.0 SSX2 SSX1 KIT
7 biphasic synovial sarcoma 32.8 SSX2 SSX1 EWSR1
8 small intestinal sarcoma 32.8 KIT EWSR1
9 osteogenic sarcoma 32.8 TP53 RB1 JUN HOTAIR FAU CHEK2
10 lung sarcoma 32.8 SSX2 SSX1 EWSR1
11 rhabdomyosarcoma 32.7 TP53 SSX2 SSX1 RB1 KRAS KIT
12 rhabdoid cancer 32.7 TP53 SSX2 EWSR1
13 leiomyosarcoma 32.7 TP53 RB1 KIT CHEK2
14 epithelioid cell synovial sarcoma 32.7 SSX2 SSX1 EWSR1
15 fibrosarcoma 32.6 TP53 KIT JUN EWSR1
16 muscle cancer 32.6 TP53 SSX2 SSX1 KIT HRAS EWSR1
17 extraskeletal ewing sarcoma 32.6 FLI1 EWSR1
18 spindle cell synovial sarcoma 32.5 SSX2 SSX1
19 embryonal rhabdomyosarcoma 32.5 TP53 KRAS HRAS EWSR1
20 myxoid liposarcoma 32.5 TP53 SSX2 SSX1 EWSR1
21 bone giant cell sarcoma 32.5 TP53 KRAS HRAS
22 hemangiopericytoma, malignant 32.5 SSX2 SSX1 KIT
23 uterine carcinosarcoma 32.5 TP53 KIT HRAS
24 carcinosarcoma 32.4 TP53 KRAS KIT HRAS
25 gastrointestinal stromal tumor 32.3 TP53 KRAS KIT HOTAIR BRAF
26 chondrosarcoma, extraskeletal myxoid 32.2 SSX2 SSX1 EWSR1
27 myxofibrosarcoma 32.2 TP53 SSX2 KRAS KIT EWSR1 BACH1-IT2
28 wilms tumor 1 32.2 TP53 KRAS FLI1 EWSR1 CHEK2 BRAF
29 angiosarcoma 32.1 TP53 KRAS KIT FLI1
30 myeloid leukemia 32.0 TP53 LYN KRAS KIT HRAS FES
31 giant cell glioblastoma 31.9 TP53 HRAS BRAF
32 mesenchymal cell neoplasm 31.9 TP53 SSX2 KIT EWSR1
33 liver angiosarcoma 31.7 TP53 KRAS
34 dedifferentiated liposarcoma 31.6 TP53 SSX2 RB1 KIT EWSR1
35 rhabdomyosarcoma 2 31.6 SSX2 SSX1 RB1 EWSR1
36 adenocarcinoma 31.6 TP53 RB1 KRAS KIT HRAS BRAF
37 hemangioma 31.6 TP53 KRAS KIT FLI1
38 leukemia, acute lymphoblastic 31.5 TP53 SRC RB1 LYN KRAS KIT
39 leukemia, acute myeloid 31.5 TP53 SRC LYN KRAS KIT JUN
40 well-differentiated liposarcoma 31.4 TP53 SSX2 SSX1 KIT EWSR1
41 exanthem 31.4 KRAS KIT HRAS
42 skin carcinoma 31.4 TP53 SRC KRAS KIT JUN HRAS
43 lymphangioma 31.4 TP53 KRAS HRAS
44 melanoma 31.3 TP53 RB1 KRAS KIT JUN HRAS
45 acute promyelocytic leukemia 31.3 TP53 SRC RB1 LYN KRAS JUN
46 connective tissue benign neoplasm 31.3 TP53 KIT EWSR1
47 myelofibrosis 31.3 TP53 SRC LYN KIT HRAS
48 skin melanoma 31.2 TP53 SRC KRAS KIT HRAS BRAF
49 cellular myxoid liposarcoma 31.2 SSX2 SSX1 EWSR1
50 myoma 31.2 TP53 KRAS KIT

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.62 HRAS KRAS BRAF
2 Decreased viability GR00055-A-2 10.62 HRAS KRAS BRAF
3 Decreased viability GR00055-A-3 10.62 KRAS
4 Decreased viability GR00106-A-0 10.62 KRAS
5 Decreased viability GR00221-A-1 10.62 HRAS KRAS KIT
6 Decreased viability GR00221-A-2 10.62 CHEK2 HRAS JUN KRAS YES1
7 Decreased viability GR00221-A-3 10.62 CHEK2 HRAS JUN YES1 LYN
8 Decreased viability GR00221-A-4 10.62 CHEK2 YES1 BRAF
9 Decreased viability GR00249-S 10.62 JUN BRAF
10 Decreased viability GR00301-A 10.62 KRAS BRAF KIT SRC
11 Decreased viability GR00342-S-2 10.62 CHEK2
12 Decreased viability GR00381-A-1 10.62 KRAS BRAF
13 Decreased viability GR00386-A-1 10.62 JUN
14 Decreased cell migration GR00055-A-1 10.02 LYN FES YES1
15 Decreased cell migration GR00055-A-3 10.02 BRAF HRAS LYN
16 Decreased substrate adherent cell growth GR00193-A-1 9.96 KIT
17 Decreased substrate adherent cell growth GR00193-A-2 9.96 KIT YES1
18 Decreased substrate adherent cell growth GR00193-A-3 9.96 BRAF CHEK2 YES1
19 Decreased substrate adherent cell growth GR00193-A-4 9.96 BRAF CHEK2 KIT YES1
20 Decreased viability in CMK cells GR00105-A-0 8.65 SRC
21 Increased telomerase activity GR00156-A 8.32 SRC

MGI Mouse Phenotypes related to Sarcoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.33 BRAF CHEK2 FES FLI1 HRAS JUN
2 hematopoietic system MP:0005397 10.31 BRAF CHEK2 FES FLI1 JUN KIT
3 immune system MP:0005387 10.3 BRAF CHEK2 FES FLI1 JUN KIT
4 mortality/aging MP:0010768 10.3 BRAF CHEK2 FAU FES FLI1 HRAS
5 craniofacial MP:0005382 10.27 BRAF FES HRAS JUN KIT KRAS
6 integument MP:0010771 10.25 BRAF FES HRAS JUN KIT KRAS
7 nervous system MP:0003631 10.18 BRAF CHEK2 FES FLI1 HRAS JUN
8 digestive/alimentary MP:0005381 10.16 BRAF FES HRAS KIT KRAS LYN
9 liver/biliary system MP:0005370 10.13 BRAF FES FLI1 JUN KIT KRAS
10 limbs/digits/tail MP:0005371 10.1 BRAF JUN KIT KRAS LYN RB1
11 neoplasm MP:0002006 10.1 BRAF CHEK2 FES FLI1 HRAS KIT
12 muscle MP:0005369 10.03 BRAF FES FLI1 HRAS KIT KRAS
13 normal MP:0002873 9.97 BRAF FES HRAS JUN KIT KRAS
14 renal/urinary system MP:0005367 9.76 BRAF HRAS KIT KRAS LYN RB1
15 pigmentation MP:0001186 9.73 BRAF KIT KRAS RB1 SRC TP53
16 respiratory system MP:0005388 9.65 BRAF HRAS JUN KIT KRAS LYN
17 skeleton MP:0005390 9.36 BRAF FES HRAS JUN KIT KRAS

Drugs & Therapeutics for Sarcoma

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 507)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
2
Lopinavir Approved Phase 4 192725-17-0 92727
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
5
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
6
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Nevirapine Approved Phase 4 129618-40-2 4463
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
11
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
12
tannic acid Approved Phase 4 1401-55-4
13
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
14
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
15
Tranexamic Acid Approved Phase 4 1197-18-8 5526
16
Dalteparin Approved Phase 4 9005-49-6
17
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
18
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
19
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
20
Enoxaparin Approved Phase 4 9005-49-6 772
21
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
22 Reverse Transcriptase Inhibitors Phase 4
23 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
24 Immunosuppressive Agents Phase 4
25 Immunologic Factors Phase 4
26 Anti-Infective Agents Phase 4
27 Antibiotics, Antitubercular Phase 4
28 Anti-Bacterial Agents Phase 4
29 Antifungal Agents Phase 4
30 Calcineurin Inhibitors Phase 4
31 Antifibrinolytic Agents Phase 4
32 Coagulants Phase 4
33 Hemostatics Phase 4
34 Anticoagulants Phase 4
35 Fibrinolytic Agents Phase 4
36 Heparin, Low-Molecular-Weight Phase 4
37 calcium heparin Phase 4
38 Platelet Aggregation Inhibitors Phase 4
39 Antipyretics Phase 4
40
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
41
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
42
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
43
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
44
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
45
Olaparib Approved Phase 3 763113-22-0 23725625
46
Palbociclib Approved, Investigational Phase 3 571190-30-2 11431660 5005498 5330286
47
Trametinib Approved Phase 3 871700-17-3 11707110
48
Ceritinib Approved Phase 3 1032900-25-6
49
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760 44516822
50
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095

Interventional clinical trials:

(show top 50) (show all 1415)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
4 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Completed NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
5 Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
6 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
7 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
8 Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years Recruiting NCT04033081 Phase 4
9 Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial Recruiting NCT04347122 Phase 4 Tranexamic Acid (TXA)
10 Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial Recruiting NCT04448873 Phase 4 Sirolimus
11 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
12 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
13 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
15 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
17 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
18 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
19 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
20 A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma Unknown status NCT02449343 Phase 2, Phase 3 Anlotinib;Placebo
21 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
22 A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
23 European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
24 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
25 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) Unknown status NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
26 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
27 Establishment of an Indication-based Identification and Psychosocial Treatment of Orthopedic Cancer Patients Suffering From Psychosocial Stress Completed NCT01631175 Phase 3
28 Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
29 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
30 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
31 A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas Completed NCT00538239 Phase 3 ridaforolimus;Placebo
32 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
33 Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma Completed NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
34 Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
35 Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
36 A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma Completed NCT00002445 Phase 3 IM862
37 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
38 Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
39 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
40 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
41 Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
42 A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
43 A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
44 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
45 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
46 A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies. Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
47 A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
48 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
49 A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma Completed NCT02672527 Phase 3 Trabectedin;Dexamethasone
50 A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma. Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ifosfamide
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

# Genetic test Affiliating Genes
1 Sarcoma 29

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

40
Bone, Myeloid, Liver, Breast, Kidney, Uterus, Skin

Publications for Sarcoma

Articles related to Sarcoma:

(show top 50) (show all 30527)
# Title Authors PMID Year
1
Nonsense-mediated mRNA decay: terminating erroneous gene expression. 6
15145354 2004
2
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. 54 61
20526094 2010
3
Sarcoma of the cervical spine after radiation treatment for thyroid cancer. 54 61
20375775 2010
4
IGF-1R targeted treatment of sarcoma. 54 61
20036195 2010
5
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. 54 61
20031388 2010
6
[A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult]. 54 61
20168062 2010
7
ALK+ anaplastic large cell lymphoma with cohesive, perivascular arrangements on cytology, mimicking a soft tissue sarcoma: a report of 2 cases. 54 61
20306994 2010
8
Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. 61 54
19376842 2010
9
Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. 61 54
19577358 2010
10
v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior. 54 61
19955937 2009
11
Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. 61 54
19647855 2009
12
Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. 54 61
19540561 2009
13
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. 54 61
19789339 2009
14
Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. 54 61
19532136 2009
15
Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. 54 61
19737974 2009
16
A case of histiocytic sarcoma diagnosed by bone marrow biopsy in a patient suffering from fever for 8 months. 61 54
19726888 2009
17
Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. 61 54
19408047 2009
18
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. 61 54
19366796 2009
19
[A sarcoma of the colonic wall with desmin expression]. 61 54
19364593 2009
20
IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. 61 54
19155307 2009
21
Low-grade fibromyxoid sarcoma versus fibromatosis: a comparative study of clinicopathological and immunohistochemical features. 61 54
19021197 2009
22
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. 61 54
18855347 2008
23
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. 61 54
19010839 2008
24
New targets for therapy of sarcoma. 61 54
18525335 2008
25
Leukemic transformation of Langerhans cell sarcoma. 61 54
18360746 2008
26
Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. 54 61
18301244 2008
27
Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. 61 54
18305103 2008
28
[Diffuse expression of KIT in a pulmonary artery sarcoma]. 61 54
18516991 2008
29
Inhibition of PKCalpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412. 54 61
18507025 2008
30
Down-regulation of plakoglobin in soft tissue sarcoma is associated with a higher risk of pulmonary metastasis. 61 54
18507004 2008
31
Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. 61 54
18199156 2008
32
Pulmonary artery sarcoma mimicking a pulmonary embolism. 61 54
18453737 2008
33
Can sparsely and heterogeneously expressed proteins be detected using tissue microarrays? A simulation study of the hypoxia marker carbonic anhydrase IX (CA IX) in human soft tissue sarcoma. 54 61
18180112 2008
34
Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma. 61 54
18176180 2008
35
Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. 54 61
17912356 2007
36
Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. 61 54
18474006 2007
37
Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. 61 54
17572079 2007
38
Expression of MYCN in pediatric synovial sarcoma. 54 61
17464317 2007
39
High prevalence of p53 exon 4 mutations in soft tissue sarcoma. 54 61
17429838 2007
40
Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. 61 54
17334346 2007
41
Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. 61 54
17287860 2007
42
Markers of angiogenesis and clinical features in patients with sarcoma. 54 61
17265525 2007
43
Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. 54 61
17264755 2007
44
Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. 54 61
17224268 2007
45
Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice. 61 54
16857722 2007
46
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. 61 54
17126255 2006
47
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. 54 61
16528479 2006
48
[Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance]. 54 61
17152492 2006
49
Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cell lines. 54 61
16705697 2006
50
Immunohistochemical analysis of embryonal sarcoma of the liver. 61 54
16785789 2006

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

6 (show all 17)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CHEK2 NM_007194.4(CHEK2):c.341G>A (p.Trp114Ter) SNV Pathogenic 560005 rs1555927374 GRCh37: 22:29121334-29121334
GRCh38: 22:28725346-28725346
2 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
3 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg) SNV Uncertain significance 141928 rs371085910 GRCh37: 5:112111352-112111352
GRCh38: 5:112775655-112775655
4 MSH2 NM_000251.3(MSH2):c.128A>G (p.Tyr43Cys) SNV Uncertain significance 90619 rs17217723 GRCh37: 2:47630458-47630458
GRCh38: 2:47403319-47403319
5 TP53 NM_000546.5(TP53):c.460G>A (p.Gly154Ser) SNV not provided 133284 rs137852789 GRCh37: 17:7578470-7578470
GRCh38: 17:7675152-7675152
6 TP53 NM_001276697.2(TP53):c.-28_-19del Deletion not provided 133283 rs137852791 GRCh37: 17:7578471-7578480
GRCh38: 17:7675153-7675162
7 TP53 NM_001276697.2(TP53):c.-30_-19del Deletion not provided 133282 rs137852790 GRCh37: 17:7578471-7578482
GRCh38: 17:7675153-7675164
8 TP53 NM_000546.5(TP53):c.969G>A (p.Leu323=) SNV not provided 132974 rs672601297 GRCh37: 17:7576877-7576877
GRCh38: 17:7673559-7673559
9 TP53 NM_000546.6(TP53):c.886C>T (p.His296Tyr) SNV not provided 132973 rs672601296 GRCh37: 17:7577052-7577052
GRCh38: 17:7673734-7673734
10 KRAS NM_033360.4(KRAS):c.219G>A (p.Arg73=) SNV not provided 132971 rs104886027 GRCh37: 12:25380239-25380239
GRCh38: 12:25227305-25227305
11 KRAS NM_033360.4(KRAS):c.216G>A (p.Met72Ile) SNV not provided 132970 rs104886028 GRCh37: 12:25380242-25380242
GRCh38: 12:25227308-25227308
12 FGFR3 NM_000142.5(FGFR3):c.2135G>A (p.Arg712His) SNV not provided 132968 rs104886024 GRCh37: 4:1808377-1808377
GRCh38: 4:1806650-1806650
13 PIK3CA NM_006218.2:c.1821+51A>T SNV not provided 132966 GRCh37:
GRCh38:
14 FGFR3 NM_000142.5(FGFR3):c.1935C>T (p.Leu645=) SNV not provided 132959 rs104886006 GRCh37: 4:1807876-1807876
GRCh38: 4:1806149-1806149
15 FGFR3 NM_000142.5(FGFR3):c.1908C>G (p.Phe636Leu) SNV not provided 132958 rs104886005 GRCh37: 4:1807849-1807849
GRCh38: 4:1806122-1806122
16 FGFR3 NM_000142.5(FGFR3):c.1887C>T (p.Asn629=) SNV not provided 132957 rs104886004 GRCh37: 4:1807828-1807828
GRCh38: 4:1806101-1806101
17 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV not provided 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303

Expression for Sarcoma

Search GEO for disease gene expression data for Sarcoma.

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TP53 SRC RB1 KRAS KIT JUN
2
Show member pathways
13.8 TP53 SRC RB1 LYN KRAS KIT
3
Show member pathways
13.6 YES1 SRC LYN KRAS KIT JUN
4
Show member pathways
13.46 YES1 TP53 SRC LYN KRAS KIT
5
Show member pathways
13.31 TP53 SRC RB1 LYN KRAS JUN
6
Show member pathways
13.17 TP53 SRC LYN KRAS KIT HRAS
7
Show member pathways
13.09 TP53 SRC KRAS JUN HRAS BRAF
8
Show member pathways
13.05 TP53 SRC RB1 LYN KRAS JUN
9
Show member pathways
13.01 SRC RB1 KRAS JUN HRAS BRAF
10
Show member pathways
12.99 SRC LYN KRAS JUN HRAS BRAF
11
Show member pathways
12.93 SRC KRAS JUN HRAS BRAF
12
Show member pathways
12.92 TP53 SRC KRAS JUN HRAS FES
13
Show member pathways
12.91 SRC LYN KRAS JUN HRAS BRAF
14 12.91 TP53 RB1 KRAS KIT JUN HRAS
15
Show member pathways
12.89 SRC KRAS JUN HRAS BRAF
16 12.87 TP53 KRAS KIT JUN HRAS BRAF
17
Show member pathways
12.85 TP53 SRC RB1 KRAS JUN HRAS
18
Show member pathways
12.84 SRC KRAS KIT HRAS BRAF
19
Show member pathways
12.84 TP53 SRC LYN KRAS KIT HRAS
20
Show member pathways
12.84 SRC LYN KRAS KIT JUN HRAS
21
Show member pathways
12.82 TP53 SRC KRAS JUN HRAS BRAF
22
Show member pathways
12.79 TP53 RB1 KRAS KIT JUN HRAS
23
Show member pathways
12.78 TP53 KRAS JUN HRAS CHEK2
24
Show member pathways
12.78 SRC RB1 KRAS JUN HRAS
25
Show member pathways
12.78 TP53 RB1 KRAS JUN HRAS BRAF
26
Show member pathways
12.77 SRC LYN KRAS JUN HRAS BRAF
27
Show member pathways
12.76 SRC KRAS JUN HRAS BRAF
28
Show member pathways
12.7 TP53 SRC KRAS HRAS FES
29
Show member pathways
12.7 TP53 SRC RB1 KRAS JUN HRAS
30
Show member pathways
12.69 SRC LYN KRAS JUN HRAS
31
Show member pathways
12.69 SRC LYN KRAS JUN HRAS
32
Show member pathways
12.6 SRC KRAS JUN HRAS BRAF
33
Show member pathways
12.57 TP53 SRC KRAS JUN HRAS BRAF
34
Show member pathways
12.56 TP53 KRAS JUN HRAS CHEK2
35
Show member pathways
12.53 LYN KRAS JUN HRAS
36
Show member pathways
12.52 LYN KRAS JUN HRAS BRAF
37
Show member pathways
12.51 SRC LYN KRAS HRAS
38
Show member pathways
12.5 SRC KRAS JUN HRAS
39
Show member pathways
12.49 KRAS KIT JUN HRAS
40
Show member pathways
12.45 YES1 SRC KRAS KIT JUN HRAS
41
Show member pathways
12.44 TP53 KRAS JUN HRAS
42
Show member pathways
12.44 YES1 SRC KRAS JUN HRAS BRAF
43 12.42 TP53 SRC KRAS HRAS BRAF
44
Show member pathways
12.41 YES1 SRC KRAS HRAS
45
Show member pathways
12.41 SRC KRAS JUN HRAS BRAF
46
Show member pathways
12.4 SRC KRAS HRAS BRAF
47 12.39 TP53 SSX2 SSX1 FLI1 EWSR1
48
Show member pathways
12.38 SRC KRAS HRAS BRAF
49
Show member pathways
12.37 SRC KRAS JUN HRAS
50 12.37 TP53 RB1 KRAS JUN HRAS CHEK2

GO Terms for Sarcoma

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynaptic specialization, intracellular component GO:0099091 9.13 YES1 SRC LYN
2 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.02 YES1 SRC LYN KRAS FES

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.18 TP53 SSX2 SSX1 RB1 JUN FLI1
2 cell differentiation GO:0030154 10.11 YES1 SRC RB1 LYN FLI1 FES
3 phosphorylation GO:0016310 10 YES1 SRC LYN KIT FES CHEK2
4 protein phosphorylation GO:0006468 9.98 YES1 SRC LYN KIT FES CHEK2
5 positive regulation of gene expression GO:0010628 9.97 TP53 SRC KRAS KIT HRAS BRAF
6 positive regulation of protein phosphorylation GO:0001934 9.9 LYN KRAS HRAS CHEK2
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.81 SRC LYN KRAS HRAS
8 cellular response to drug GO:0035690 9.79 TP53 CHEK2 BRAF
9 ephrin receptor signaling pathway GO:0048013 9.78 YES1 SRC LYN HRAS
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.77 YES1 SRC LYN KIT FES
11 T cell costimulation GO:0031295 9.76 YES1 SRC LYN
12 visual learning GO:0008542 9.73 KRAS KIT BRAF
13 protein autophosphorylation GO:0046777 9.73 YES1 SRC LYN KIT FES CHEK2
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.71 SRC LYN KIT
15 positive regulation of MAP kinase activity GO:0043406 9.71 SRC KRAS KIT HRAS
16 cellular response to gamma radiation GO:0071480 9.7 TP53 HRAS CHEK2
17 positive regulation of monocyte differentiation GO:0045657 9.63 JUN FES
18 regulation of mast cell degranulation GO:0043304 9.62 LYN FES
19 regulation of vascular permeability GO:0043114 9.62 YES1 SRC
20 peptidyl-tyrosine autophosphorylation GO:0038083 9.62 YES1 SRC LYN FES
21 response to isolation stress GO:0035900 9.61 KRAS HRAS
22 myeloid progenitor cell differentiation GO:0002318 9.59 KIT BRAF
23 response to mineralocorticoid GO:0051385 9.55 SRC KRAS
24 Ras protein signal transduction GO:0007265 9.55 TP53 RB1 KRAS JUN HRAS
25 peptidyl-tyrosine phosphorylation GO:0018108 9.43 YES1 SRC LYN KIT FES BRAF
26 regulation of cell proliferation GO:0042127 9.23 YES1 TP53 SRC LYN KIT JUN

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 10.11 YES1 SRC LYN KRAS KIT HRAS
2 ATP binding GO:0005524 10.08 YES1 TP53 SRC LYN KIT FES
3 kinase activity GO:0016301 9.95 YES1 SRC LYN KIT FES CHEK2
4 protein-containing complex binding GO:0044877 9.85 SRC LYN KRAS JUN HRAS BRAF
5 enzyme binding GO:0019899 9.8 YES1 TP53 SRC RB1 LYN JUN
6 protein kinase activity GO:0004672 9.8 YES1 SRC LYN KIT FES CHEK2
7 ubiquitin protein ligase binding GO:0031625 9.63 TP53 SRC RB1 LYN JUN CHEK2
8 phosphoprotein binding GO:0051219 9.61 SRC RB1 LYN
9 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.26 YES1 SRC LYN FES
10 protein tyrosine kinase activity GO:0004713 9.1 YES1 SRC LYN KIT FES BRAF

Sources for Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....